Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.
